Non-Fucosylated Anti-Human Apolipoprotein E Therapeutic Antibody (CAT#: BioBet-578ZP) Datasheet

APOE

apolipoprotein E

The protein encoded by this gene is a major apoprotein of the chylomicron. It binds to a specific liver and peripheral cell receptor, and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. This gene maps to chromosome 19 in a cluster with the related apolipoprotein C1 and C2 genes. Mutations in this gene result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants. Alternative splicing results in multiple transcript variants.

APOE; apolipoprotein E; AD2; LPG; APO-E; LDLCQ

Extracellular region or secreted

Diseases associated with APOE include Lipoprotein Glomerulopathy and Hyperlipoproteinemia, Type Iii.

Its related pathways are Neuroscience and Lipoprotein metabolism.

APOE is an apolipoprotein related to lipid particles, which mainly acts on lipoprotein-mediated lipid transport between organs through plasma and interstitial fluid. APOE is the core component of plasma lipoproteins and is involved in the production, transformation and clearance of lipoproteins. A major function of APOE is to mediate lipoprotein clearance through uptake of chylomicrons, VLDLs and HDLs by hepatocytes. APOE is also involved in the biosynthesis of VLDLs in the liver and the uptake by peripheral tissues, ensuring the delivery of triglycerides and the energy storage of muscle, heart and adipose tissue. APOE plays a key role in plasma and tissue lipid homeostasis by participating in lipoprotein-mediated lipid distribution between tissues. APOE is also involved in the two steps of cholesterol reverse transport, that is, HDL-mediated transport of cholesterol from peripheral tissues to the liver, thus playing an important role in cholesterol homeostasis.

Synthesized with the sialic acid attached by O-glycosidic linkage and is subsequently desialylated in plasma. O-glycosylated with core 1 or possibly core 8 glycans. Thr-307 and Ser-314 are minor glycosylation sites compared to Ser-308. Glycated in plasma VLDL of normal subjects, and of hyperglycemic diabetic patients at a higher level (2-3 fold). Phosphorylated by FAM20C in the extracellular medium.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

BioBet-578ZP

Humanized

Human

Anti-ApoE antibody is used for treating Alzheimer's disease. Apolipoprotein E (apoE) is the strongest known genetic risk factor for late onset Alzheimer's disease (AD). It influences amyloid-β (Aβ) clearance and aggregation, which likely contributes in large part to its role in AD pathogenesis.

Alzheimer's Disease

Alzheimer's Disease